Ajanta Pharma Ltd., incorporated in the year 1979, is a Mid Cap company (having a market cap of Rs 20260.98 Crore) operating in Pharmaceuticals sector.
Financials
For the quarter ended 31-03-2021, the company reported a Consolidated Total Income of Rs 759.37 Crore, up .68 % from last quarter Total Income of Rs 754.22 Crore and up 2.81 % from last year same quarter Total Income of Rs 738.65 Crore. Company reported net profit after tax of Rs 159.26 Crore in latest quarter.
Investment Rationale
The brokerage remains positive on AJP on a) new launches and market share gains in the key markets of the US/DF/Asia/Africa, b) the benefits of major capex (to accrue over the next 2–3 years), c) improved operating leverage, and d) enhanced MR productivity.
Promoter/FII Holdings
Promoters held 70.3 per cent stake in the company as of June 30, 2021, while FIIs held 8.9 per cent, DIIs 12.3 per cent and public and others 8.5 per cent.
(Disclaimer: Views and recommendations given in this section are the analysts’ own and do not represent those of ETMarkets.com. Please consult your financial adviser before taking any position in the stock/s mentioned.
